FI104954B - System för kontrollerat administrering av läkemedel omfattande interaktion av protein eller polypeptid och bionedbrytbara polymerer - Google Patents

System för kontrollerat administrering av läkemedel omfattande interaktion av protein eller polypeptid och bionedbrytbara polymerer Download PDF

Info

Publication number
FI104954B
FI104954B FI913455A FI913455A FI104954B FI 104954 B FI104954 B FI 104954B FI 913455 A FI913455 A FI 913455A FI 913455 A FI913455 A FI 913455A FI 104954 B FI104954 B FI 104954B
Authority
FI
Finland
Prior art keywords
polymer
calcitonin
solvent
protein
polypeptide
Prior art date
Application number
FI913455A
Other languages
English (en)
Finnish (fi)
Other versions
FI913455A0 (fi
FI913455A (fi
Inventor
Patrick P Deluca
Original Assignee
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kentucky Res Found filed Critical Univ Kentucky Res Found
Publication of FI913455A0 publication Critical patent/FI913455A0/fi
Publication of FI913455A publication Critical patent/FI913455A/fi
Application granted granted Critical
Publication of FI104954B publication Critical patent/FI104954B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Adjustment And Processing Of Grains (AREA)

Claims (5)

1. Förfarande for framställning av ett system för läkemedelsadministremg med fördröjd ut-lösning, kännetecknat därav att det omfattar följande steg: a) kalcitonin och en hydrofob, bionedbrytbar polymer vald ur gruppen bestäende av polygly-kolsyra, polymjölksyra, kopolymer av glykolsyra och L- eller D,L-mjölksyra samt kopolymer 15 av glykolid och L- eller D,L-laktid, löses i ett första lösningsmedel i vilket kalcitoninet och polymeren är lösliga men som inte sönderdelar polymeren eller kalcitoninet eller inverkar skadligt pä dem; b) altemativt i) lösningen dispergeras i ett andra lösningsmedel i vilket polymeren inte är 20 löslig och som emulgerar det första lösningsmedlet varvid mikrodroppar uppstär, varefler det första lösningsmedlet avlägsnas ur mikrodroppama genom extraktion eller indunstning sä, att i gränsytan mellan polymeren och vattnet uppstär en växelverkan som orsakar bindning av kalcitoninet tili polymeren, och polymeren härdas sä kalcitoninhaltiga mikrosfärer uppstär; eller 25 ii) ett andra lösningsmedel tillsätts i vilket kalcitonin men inte polymeren löser sig, för att utfälla mikropartiklar i vilka kalcitoninet har adsorberats.
2. Förfarande enligt patentkrav 1, kännetecknat därav att de nämnda första och andra lösningsmedlen avlägsnas genom fiystorkning frän den dispersion de har bildat. 30
3. Förfarande enligt patentkrav 1 eller 2, kännetecknat därav att storleken hos mikropar-tiklama förminskas. 30 104954
4. Förfarande enligt nägot av patentkrav 1-3, kännetecknat därav att det första lös-ningsmedlet är valt ur gruppen bestäende av metylenklorid, hexafluoraceton och hexa-fluorisopropanol. 5
5. Förfarande enligt nägot av patentkrav 1 - 4, kännetecknat därav att det andra lös-ningsmedlet är valt ur gruppen bestäende av vatien, vattenbaserad buffertlösning och vatten-alkoholblandning. «
FI913455A 1990-07-19 1991-07-17 System för kontrollerat administrering av läkemedel omfattande interaktion av protein eller polypeptid och bionedbrytbara polymerer FI104954B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55442790A 1990-07-19 1990-07-19
US55442790 1990-07-19

Publications (3)

Publication Number Publication Date
FI913455A0 FI913455A0 (fi) 1991-07-17
FI913455A FI913455A (fi) 1992-01-20
FI104954B true FI104954B (sv) 2000-05-15

Family

ID=24213291

Family Applications (1)

Application Number Title Priority Date Filing Date
FI913455A FI104954B (sv) 1990-07-19 1991-07-17 System för kontrollerat administrering av läkemedel omfattande interaktion av protein eller polypeptid och bionedbrytbara polymerer

Country Status (17)

Country Link
US (2) US6306406B1 (sv)
EP (1) EP0467389B1 (sv)
JP (1) JPH05103838A (sv)
AT (1) ATE185269T1 (sv)
AU (1) AU656897B2 (sv)
CA (1) CA2046830C (sv)
CS (1) CS224891A3 (sv)
DE (1) DE69131677T2 (sv)
DK (1) DK0467389T3 (sv)
ES (1) ES2138584T3 (sv)
FI (1) FI104954B (sv)
GR (1) GR3032056T3 (sv)
MX (1) MX9100249A (sv)
NO (1) NO304411B1 (sv)
NZ (1) NZ238951A (sv)
PT (1) PT98397B (sv)
ZA (1) ZA915584B (sv)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447728A (en) * 1992-06-15 1995-09-05 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US5451410A (en) * 1993-04-22 1995-09-19 Emisphere Technologies, Inc. Modified amino acids for encapsulating active agents
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5629020A (en) 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US6221367B1 (en) 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US5541155A (en) 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US5693338A (en) 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US5443841A (en) * 1992-06-15 1995-08-22 Emisphere Technologies, Inc. Proteinoid microspheres and methods for preparation and use thereof
US5578323A (en) * 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US6099856A (en) 1992-06-15 2000-08-08 Emisphere Technologies, Inc. Active agent transport systems
JPH05202177A (ja) * 1991-09-06 1993-08-10 Teijin Ltd 生分解性共重合体、及びそれを含有する医薬品組成物
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5811127A (en) 1992-06-15 1998-09-22 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
ES2110573T3 (es) * 1992-08-07 1998-02-16 Takeda Chemical Industries Ltd Produccion de microcapsulas de farmacos solubles en agua.
WO1994010980A1 (en) * 1992-11-16 1994-05-26 Corporation Of Mercer University Compositions using microencapsulated neutralizing antibodies
UA61046C2 (en) 1992-12-07 2003-11-17 Takeda Chemical Industries Ltd Sustained-release preparation and method for its manufacture
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5401516A (en) * 1992-12-21 1995-03-28 Emisphere Technologies, Inc. Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
CA2150574A1 (en) * 1993-01-06 1994-07-21 Shalaby W. Shalaby Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US6221958B1 (en) 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5863985A (en) * 1995-06-29 1999-01-26 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5672659A (en) * 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5958457A (en) 1993-04-22 1999-09-28 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US5709861A (en) 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
DE69428040T2 (de) 1993-04-22 2002-05-29 Emisphere Technologies, Inc. Orale darreichungsform
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6087324A (en) * 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
KR100369764B1 (ko) * 1994-07-20 2003-05-22 키너톤 리미티드 생분해성폴리에스테르및생활성폴리펩티드의이온성분자결합체
US6090958A (en) 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
CN1151836C (zh) 1995-03-31 2004-06-02 艾米斯菲尔技术有限公司 用作传送活性剂的化合物和组合物
US6001347A (en) 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5989539A (en) 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5965121A (en) 1995-03-31 1999-10-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5820881A (en) 1995-04-28 1998-10-13 Emisphere Technologies, Inc. Microspheres of diamide-dicarboxylic acids
US5667806A (en) 1995-06-07 1997-09-16 Emisphere Technologies, Inc. Spray drying method and apparatus
US5824345A (en) 1995-06-07 1998-10-20 Emisphere Technologies, Inc. Fragrances and flavorants
US5750147A (en) 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
US6051258A (en) 1995-06-07 2000-04-18 Emisphere Technologies, Inc. Proteinoid emulsions and methods for preparation and use thereof
CA2224381A1 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
GB2320248B (en) 1995-09-11 1999-04-14 Emisphere Tech Inc Method for preparing omega-aminoalkanoic acid derivatives from cycloalkanones
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
AU717113B2 (en) 1995-11-09 2000-03-16 Health Protection Agency Microencapsulated DNA for vaccination and gene therapy
EP0904065A4 (en) 1996-06-14 2000-06-14 Emisphere Tech Inc MICRO-ENCLOSED FRAGRANCES AND PRODUCTION METHOD
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
AU779930B2 (en) * 1996-12-11 2005-02-17 Praecis Pharmaceuticals Incorporated Pharmaceutical formulations for sustained drug delivery
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
US6313088B1 (en) 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US5804688A (en) 1997-02-07 1998-09-08 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5939381A (en) 1997-02-07 1999-08-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5879681A (en) 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US5990166A (en) 1997-02-07 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5876710A (en) 1997-02-07 1999-03-02 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
US6060513A (en) 1997-02-07 2000-05-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5863944A (en) 1997-04-30 1999-01-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5962710A (en) 1997-05-09 1999-10-05 Emisphere Technologies, Inc. Method of preparing salicyloylamino acids
US6867181B1 (en) 1997-06-02 2005-03-15 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
DE19723807C2 (de) * 1997-06-06 2003-04-24 Ferring Gmbh Verfahren zur Herstellung von Copolyestern
CN1264310A (zh) * 1997-07-25 2000-08-23 Sdg有限公司 靶向传递生物活性剂的基于聚合物的药物组合物
IL122933A (en) * 1998-01-14 2005-03-20 Efrat Biopolymers Ltd Polymeric carrier for delivery of a bioactive molecule
PL342135A1 (en) 1998-01-29 2001-05-21 Kinerton Ltd Method of obtaining absorbable microparticle
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
CA2335460A1 (en) 1998-06-18 1999-12-23 Johns Hopkins University School Of Medicine Polymers for delivery of nucleic acids
US6916490B1 (en) 1998-07-23 2005-07-12 UAB Research Center Controlled release of bioactive substances
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
CA2439120C (en) 2001-02-23 2011-07-05 Genentech, Inc. Erodible polymers for injection
AU2002337692B2 (en) 2001-09-26 2007-09-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
DE10206517A1 (de) * 2002-02-16 2003-09-04 Stoess & Co Gelatine Depotarzneimittel, Trägermaterialien für Depotarzneimittel und Verfahren zu deren Herstellung
KR100405879B1 (ko) * 2002-09-19 2003-11-14 키너톤 리미티드 생분해성 폴리에스테르 및 생활성 폴리펩티드의 이온성분자 결합체
US8133505B2 (en) 2002-10-31 2012-03-13 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
IL152574A (en) * 2002-10-31 2009-09-22 Transpharma Medical Ltd A system for passing through the skin of dry items or dried medicines
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
RU2543350C2 (ru) 2003-01-28 2015-02-27 Айронвуд Фармасьютикалз, Инк. Способы и композиции для лечения желудочно-кишечных расстройств
US7393537B2 (en) * 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
ES2315664T3 (es) 2003-06-30 2009-04-01 Domantis Limited Anticuerpos de dominio unico (dab) pegilados.
PL1682537T3 (pl) 2003-11-05 2012-09-28 Sarcode Bioscience Inc Modulatory adhezji komórkowej
CA2552758A1 (en) * 2004-01-13 2005-08-04 Vasogenix Pharmaceuticals, Inc. Methods for treating acute myocardial infarction by administering calcitonin gene related peptide and compositions containing the same
EP1703915A2 (en) * 2004-01-13 2006-09-27 Vasogenix Pharmaceuticals, Inc. Methods of using cgrp for cardiovascular and renal indications
JP2007517912A (ja) * 2004-01-13 2007-07-05 バソジェニックス ファーマシューティカルズ， インコーポレイテッド 心脈管および腎臓の適応症のための制御放出ｃｇｒｐ送達組成物
EP1711163A2 (en) * 2004-02-05 2006-10-18 Baxter International Inc. Dispersions prepared by use of self-stabilizing agents
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
JP5794721B2 (ja) 2005-05-17 2015-10-14 サーコード バイオサイエンス インコーポレイテッド 眼障害の治療のための組成物および方法
US20070142287A1 (en) * 2005-12-20 2007-06-21 Biomed Solutions, Llc Compositions And Methods For Treatment Of Cancer
US20100222875A1 (en) * 2006-08-08 2010-09-02 Abbott Cardiovascular Systems Inc. Method for forming a porous stent coating
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EA020466B1 (ru) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
AU2008317473B2 (en) 2007-10-19 2014-07-17 Bausch + Lomb Ireland Limited Compositions and methods for treatment of diabetic retinopathy
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
MX2011000501A (es) 2008-07-18 2011-05-23 Squibb Bristol Myers Co Composiciones monovalentes para union a cd28 y metodos de uso.
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
CA2797133C (en) * 2010-04-27 2019-08-06 Zealand Pharma A/S Peptide conjugates of glp-1 receptor agonists and gastrin and their use
GB201009037D0 (en) 2010-05-28 2010-07-14 Univ Surrey Compositions and methods for treating disorders associated with atherosclerotic plaques
US8865220B2 (en) * 2010-06-14 2014-10-21 Kaohsiung Medical University Method for controlled release of parathyroid hormone from encapsulated poly(lactic-glycolic)acid microspheres
BRPI1003424A2 (pt) * 2010-09-08 2013-01-08 Univ Rio De Janeiro sistema polimÉtrico de confinamento de amilina humana e anÁlogos agonistas, processo e uso; processo de avaliaÇço funcional de amilina liberada
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2817206C (en) 2010-11-10 2020-03-10 Tengion, Inc. Injectable formulations for organ augmentation
ES2579319T3 (es) 2011-05-04 2016-08-09 Balance Therapeutics, Inc. Derivados de pentilenotetrazol
AU2013295706A1 (en) 2012-07-25 2015-02-19 Sarcode Bioscience Inc. LFA-1 inhibitor and polymorph thereof
SI2912165T1 (sl) 2012-10-24 2019-11-29 Inregen Populacije ledvičnih celic in njihova uporaba
WO2014120916A1 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Pegylated domain antibodies monovalent for cd28 binding and methods of use
EP2958577A2 (en) 2013-02-25 2015-12-30 Synergy Pharmaceuticals Inc. Guanylate cyclase receptor agonists for use in colonic cleansing
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP3054969B1 (en) 2013-10-10 2021-03-10 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
WO2017123634A1 (en) 2016-01-11 2017-07-20 Synergy Pharmaceuticals, Inc. Formulations and methods for treating ulcerative colitis
EP3840710A4 (en) * 2018-08-24 2022-05-18 North Carolina State University PATCHES WITH MICRONEEDLE ARRAYS WITH GLUCOSE SENSITIVE MATRIX FOR CLOSED CIRCUIT INSULIN DELIVERY
WO2024080308A1 (ja) * 2022-10-12 2024-04-18 中外製薬株式会社 ペプチド、界面活性剤及びポリマーを含む組成物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3843446A (en) 1971-04-20 1974-10-22 Research Corp Preparation of enzymatically active membranes
US3977941A (en) 1971-04-20 1976-08-31 Research Corporation Protein-enzyme complex membranes
US4601981A (en) 1971-04-20 1986-07-22 Research Corporation Enzymatically active protein-enzyme complex membranes
US3972776A (en) 1973-02-26 1976-08-03 Research Corporation Preparation of protein membranes containing microbial cells
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US5366734A (en) * 1981-02-16 1994-11-22 Zeneca Limited Continuous release pharmaceutical compositions
DE3107527A1 (de) 1981-02-27 1982-09-16 Klaus Prof. Dr. 8400 Regensburg Heckmann Hyperfiltrationsmembranen mit trennschichten aus monomolekularen filmen von tensiden
US4591501A (en) 1981-04-13 1986-05-27 Seton Company Cosmetic and pharmaceutical sheet material containing polypeptides
US4585797A (en) 1981-04-13 1986-04-29 Seton Company Cosmetic and pharmaceutical sheet material containing polypeptides
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4494994A (en) 1983-03-28 1985-01-22 Seton Company Surface active agent compositions containing polypeptides and lignin sulfonic acid
US4557855A (en) 1983-03-28 1985-12-10 Seton Company Surface active agent compositions
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
DE3413608A1 (de) * 1984-04-11 1985-10-24 Hoechst Ag, 6230 Frankfurt Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung
DE3428372A1 (de) * 1984-08-01 1986-02-13 Hoechst Ag, 6230 Frankfurt Mikrokapseln von regulatorischen peptiden mit kontrollierter freisetzung, verfahren zu ihrer herstellung und injektionszubereitungen
GB8500209D0 (en) 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
US4863735A (en) * 1985-02-19 1989-09-05 Massachusetts Institute Of Technology Biodegradable polymeric drug delivery system with adjuvant activity
US4897444A (en) 1985-05-31 1990-01-30 The Research Foundation Of The State University Of New York Immobilized fluorogenic substrates for enzymes; and processes for their preparation
US4871716A (en) * 1986-02-04 1989-10-03 University Of Florida Magnetically responsive, hydrophilic microspheres for incorporation of therapeutic substances and methods of preparation thereof
US4741872A (en) * 1986-05-16 1988-05-03 The University Of Kentucky Research Foundation Preparation of biodegradable microspheres useful as carriers for macromolecules
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
ES2053549T3 (es) 1986-08-11 1994-08-01 Innovata Biomed Ltd Un proceso para la preparacion de una formulacion farmaceutica apropiada para inhalacion.
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
WO1988009664A1 (en) * 1987-06-10 1988-12-15 Massachusetts Institute Of Technology Polyphosphazene matrix erosion and diffusion release systems
GB8714378D0 (en) 1987-06-19 1987-07-22 Hunchplan Ltd Parenteral delivery of drugs
US4857311A (en) * 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
EP0308181A1 (en) * 1987-09-14 1989-03-22 Novo Nordisk A/S Trans-mucosal delivery formulations and a method for preparation thereof
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
EP0354714A3 (en) 1988-08-12 1991-04-10 Hadassah Medical Organization Pharmaceutical compositions containing polyaromatic compounds
US5008116A (en) * 1988-11-14 1991-04-16 Frederick Cahn Immunostimulatory microsphere
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
AU634606B2 (en) * 1989-11-06 1993-02-25 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres

Also Published As

Publication number Publication date
PT98397B (pt) 1999-01-29
US20020051808A1 (en) 2002-05-02
PT98397A (pt) 1992-05-29
DE69131677D1 (de) 1999-11-11
AU656897B2 (en) 1995-02-23
EP0467389A2 (en) 1992-01-22
NO912769D0 (no) 1991-07-15
MX9100249A (es) 1992-02-28
EP0467389B1 (en) 1999-10-06
ES2138584T3 (es) 2000-01-16
FI913455A0 (fi) 1991-07-17
GR3032056T3 (en) 2000-03-31
CS224891A3 (en) 1992-03-18
NO304411B1 (no) 1998-12-14
FI913455A (fi) 1992-01-20
ATE185269T1 (de) 1999-10-15
EP0467389A3 (sv) 1994-02-02
CA2046830C (en) 1999-12-14
AU8046691A (en) 1992-01-23
ZA915584B (en) 1992-04-29
DK0467389T3 (da) 2000-02-28
NO912769L (no) 1992-01-20
NZ238951A (en) 1994-12-22
US6306406B1 (en) 2001-10-23
DE69131677T2 (de) 2000-02-24
JPH05103838A (ja) 1993-04-27
CA2046830A1 (en) 1992-01-20

Similar Documents

Publication Publication Date Title
FI104954B (sv) System för kontrollerat administrering av läkemedel omfattande interaktion av protein eller polypeptid och bionedbrytbara polymerer
CA2565296C (en) Sustained-release microspheres and methods of making and using same
US9877922B2 (en) Process of preparing microspheres for sustained release having improved dispersibility and syringeability
KR100293882B1 (ko) 카르복시말단폴리에스테르와펩티드와의염
CA2533592C (en) Controlled release compositions
AU2004277419B2 (en) Nanoparticulate therapeutic biologically active agents
FI109543B (sv) Förfarande för framställning av en terapeutiskt användbar oktreotidpamoat
CA2532302C (en) Method for the preparation of controlled release formulations
ES2374623T3 (es) Método de preparación de una formulación mista de microesferas de liberación controlada mediante un proceso continuo de una etapa.
KR19990071595A (ko) 형태학적으로 균일한 마이크로 캡슐의 제조 방법 및 이 방법에의해 제조된 마이크로 캡슐
JP2002526383A (ja) 薬物分子と生分解性高分子の共有結合を用いた薬物分子伝達システム
JP2867404B2 (ja) ドラッグデリバリーのための多孔性ミクロスフェアおよびその製造法
Saez et al. Microspheres as delivery systems for the controlled release of peptides and proteins
KR20110070850A (ko) 제어 방출성 펩티드 제형
CN100475264C (zh) 含干扰素或其类似物的注射用缓释微球及其制备方法
CN100528224C (zh) 含干扰素α-1b的注射用缓释微球及其制备方法
CA2535463A1 (en) Octreotide-pamoate and its use in sustained release formulations of water soluble peptides
IL112286A (en) Process for the production of a microparticle and microparticle obtained thereby
CN1754571A (zh) 含干扰素α－2b的注射用缓释微球及其制备方法

Legal Events

Date Code Title Description
MA Patent expired